EIRGENIX Business Summary

EirGenix Inc. (6589.TW) operates a dual-pillar business model as a premier biologics Contract Development and Manufacturing Organization (CDMO) and a developer of high-value biosimilars. The company generates revenue through fee-for-service CDMO contracts—covering cell line development, process optimization, and cGMP manufacturing—and through strategic licensing agreements and milestone payments from its internal pipeline, notably its HER2-targeted biosimilars like EG12014 (Trastuzumab) and EG1206A (Pertuzumab). Its primary business segments are divided into CDMO Services, which leverage mammalian and microbial production facilities in Zhubei and Xizhi, and Biologics Product Development. EirGenix competes directly with global giants such as Samsung Biologics, Lonza Group, and FUJIFILM Diosynth Biotechnologies, positioning itself as a high-density, cost-effective alternative in the Asia-Pacific region with a growing footprint in the U.S. and European markets through partnerships with Sandoz. The company is led by Founder, Chairman, and President Dr. Lee-Cheng Liu, a veteran with over 30 years of experience in the biopharmaceutical industry who previously served as COO of AnGes Inc. and held management roles at Novartis. The executive leadership team includes Dr. Chih-Jung Chang, who serves as Senior Vice President and CEO of the Biologics Manufacturing Business Unit (BMBU), and Dr. Portia Lin, the Chief Business Officer responsible for global alliance management. EirGenix maintains a high-pedigree board and investor base, with significant backing from Foxconn Technology Co., Ltd. (founded by Terry Guo) and Yonglin Capital Holding, alongside institutional support from the National Development Fund (Executive Yuan) and Formosa Laboratories. The board, re-elected for the 2025–2028 term, includes prominent industry figures such as Cheng-Yu Cheng and independent directors like Dr. Johnsee Lee, former President of the Industrial Technology Research Institute (ITRI).